A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients

被引：12

作者：

Curvo, Raphael P. M. ^{[2
]}

Zalcberg, Ilana R. ^{[3
]}

Scholl, Vanesa ^{[3
]}

Pires, Virginia ^{[3
]}

Moellmann-Coelho, Arthur ^{[4
]}

Moreira, Miguel A. M. ^{[1
]}

机构：

[1] Inst Nacl Canc, Div Genet, BR-20231050 Rio De Janeiro, Brazil

[2] Univ Fed Rio de Janeiro, Dept Genet, BR-21944970 Rio De Janeiro, Brazil

[3] Inst Nacl Canc, Bone Marrow Transplantat Ctr, BR-20230130 Rio De Janeiro, Brazil

[4] Inst Nacl Canc, Hematol Serv, BR-20230130 Rio De Janeiro, Brazil

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 03期

关键词：

D O I：

10.1016/j.leukres.2007.04.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：508 / 510

页数：3

共 10 条

[1] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[2] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[3] The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J].

Deininger, MWN ;

Goldman, JM ;

Lydon, N ;

Melo, JV .

BLOOD, 1997, 90 (09) :3691-3698

[4] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[5] A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib [J].

Gruber, F. X. ;

Hjorth-Hansen, H. ;

Mikkola, I. ;

Stenke, L. ;

Johansen, T. .

LEUKEMIA, 2006, 20 (11) :2057-2060

[6] Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy [J].

Hochhaus, A ;

Kreil, S ;

Corbin, AS ;

La Rosée, P ;

Müller, MC ;

Lahaye, T ;

Hanfstein, B ;

Schoch, C ;

Cross, N ;

Berger, U ;

Gschaidmeier, H ;

Druker, BJ ;

Hehlmann, R .

LEUKEMIA, 2002, 16 (11) :2190-2196

[7]

KIRSCHBAUMSLAGE.N, 2004, GENET MOL RES, V30, P512

[8] Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique [J].

Kreuzer, KA ;

le Coutre, P ;

Landt, O ;

Na, LK ;

Schwarz, M ;

Schultheis, K ;

Hochhaus, A ;

Dörken, B .

ANNALS OF HEMATOLOGY, 2003, 82 (05) :284-289

[9] Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse [J].

Marin, D ;

Kaeda, J ;

Szydlo, R ;

Saunders, S ;

Fleming, A ;

Howard, J ;

Andreasson, C ;

Bua, M ;

Olavarria, E ;

Rahemtulla, A ;

Dazzi, F ;

Kanfer, E ;

Goldman, JM ;

Apperley, JF .

LEUKEMIA, 2005, 19 (04) :507-512

[10]

Wang ZN, 2003, CANCER RES, V63, P655

← 1 →